Developer docs
API playgroundTry for free, no card

Search company profiles

lumoslabs.com

Full company profile

uuid005ny9m

Namestring
lumoslabs.com
Legal namestring
Lumos Labs, Inc.
Websiteurl
lumoslabs.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Lumos Labs, Inc. is a San Francisco-based private company founded in 2005 that operates a cognitive training and assessment platform under the Lumosity brand. Its core consumer product, Lumosity Brain Training, is a web- and mobile-based subscription program of 40+ game-based training tasks across cognitive domains including attention, memory, processing speed, problem solving, flexibility, and executive functioning. Daily sessions are 15 minutes across 5 games, with difficulty adapting to individual ability. Complementing this is the NeuroCognitive Performance Test (NCPT), a validated, web-based neuropsychological assessment of 17 subtests designed for at-home unsupervised use. The company runs the Human Cognition Project (HCP), a research collaboration program providing free access to its tools and de-identified datasets to 100+ qualified academic and clinical researchers; this program has produced 130+ peer-reviewed publications and currently supports 40+ ongoing studies.

The company's commercial model today is a consumer subscription for Lumosity, with research tools offered free to qualified investigators and ancillary professional services. In 2021, Lumos Labs launched Lumosity DTx, a digital therapeutics division developing prescription digital medicine for neurological and cognitive conditions. A pivotal clinical trial is underway in adult ADHD, with proof-of-concept programs across 19 clinical populations including mild cognitive impairment, stroke, Alzheimer's, cancer-related cognitive impairment, multiple sclerosis, and traumatic brain injury. The DTx division has joined the Foundation for the National Institutes of Health Biomarkers Consortium to pursue FDA-qualified digital biomarkers. The company is incorporated in the United States, headquartered in San Francisco, and serves a global footprint through web, iOS, and Android channels.

Short descriptiontext

Lumos Labs operates the Lumosity consumer brain training subscription and the NeuroCognitive Performance Test (NCPT), serving individual subscribers, 100+ academic and clinical research partners via the Human Cognition Project, and developing prescription digital therapeutics through its Lumosity DTx division.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cognitive training software, digital therapeutics, neuropsychological assessment, brain training games, cognitive assessment platform
Industry2 codes
PRIMARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cognitive Training Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Lumosity Consumer Subscription
TypeSubscription Recurring
Description

Lumosity brain training program offered to consumers through subscription model, available on web and mobile platforms. The platform serves individual users who pay for access to cognitive training games.

lumoslabs.com
2Digital Therapeutics (DTx)
TypeSubscription Recurring
Description

Development of FDA-cleared digital medicine products for neurological and cognitive conditions. Pending clinical results, Lumosity DTx plans to seek FDA clearance for prescription DTx products targeting conditions such as adult ADHD.

lumoslabs.com
3Research Data Access
TypeData Monetisation
Description

Through the Human Cognition Project, researchers gain access to de-identified cognitive data subsets from Lumosity or NCPT. While tools are provided free to qualified researchers, this represents data monetization through research collaborations that advance scientific understanding and product development.

lumoslabs.com
4Research Services
TypeProfessional Services
Description

Lumos Labs scientists provide support on study design, data analysis, secure data storage, and regular delivery of study data for research collaborators.

lumoslabs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Free access for qualified researchers
ModelFreemiumBilling cadenceMonthly
Notes

The Human Cognition Project provides free access to Lumosity brain training games, cognitive assessments, and subsets of de-identified historical dataset for researchers with IRB approval. No pricing information for consumer subscriptions is publicly available.

lumoslabs.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 4 records shown
1Lumosity
Description

Brain training program including 40+ game-based training tasks spanning cognitive domains such as Attention, Memory, and Problem Solving.

lumoslabs.com
+3 more records
Core offering1 text field

Lumos Labs develops and operates Lumosity, a web and mobile cognitive training platform offering more than 40 brain training games spanning memory, attention, and problem solving domains. The company also provides the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment, and offers de-identified cognitive datasets plus paid research collaboration services (study design, data analysis, secure storage, data delivery) through the Human Cognition Project (HCP). The Lumosity DTx division develops prescription digital therapeutics for neurological conditions, with a pivotal clinical trial underway for adult ADHD.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 130+ peer-reviewed articles from research collaborations
+2 more records
Product overview1 text field

Lumos Labs operates a platform-plus-services model centered on cognitive training and assessment. The core product is Lumosity Brain Training, a program of 40+ cognitive games that adapt to individual ability levels. Complementing this is the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment with 17 subtests. The Human Cognition Project (HCP) provides researchers access to Lumosity software and historical datasets for academic studies. In 2021, the company launched Lumosity DTx as a new division focused on developing FDA-regulated digital therapeutics, with a pivotal clinical trial underway for adult ADHD treatment and proof-of-concept programs for conditions including MCI, stroke, and Alzheimer's Disease.

Product and service3 records
1Lumosity Brain Training
CategoryCognitive Training Software
Description

A cognitive training program with more than 40 game-based training tasks spanning cognitive domains including Attention, Memory, Problem Solving, Cognitive Flexibility, Processing Speed, and Executive Functioning. Training consists of 15-minute daily sessions with 5 games each day, with difficulty adapting to individual abilities. Distributed via web and mobile apps to individual consumers.

2NeuroCognitive Performance Test (NCPT)
CategoryNeuropsychological Assessment
Description

A validated, brief, repeatable, modular, online neuropsychological assessment platform designed by Lumos Labs for at-home, unsupervised use through a web browser. Includes 17 subtests based on well-known neuropsychological assessments measuring memory, processing speed, reasoning, attention, and cognitive flexibility. Can be administered in clinical settings.

3Lumosity DTx
CategoryDigital Therapeutics
Description

Digital therapeutics division developing prescription DTx products for neurological and cognitive conditions. Currently conducting pivotal clinical trial for adult ADHD treatment, with proof-of-concept programs for MCI, stroke, Alzheimer's, cancer-related cognitive impairment, multiple sclerosis, TBI, ASD, PTSD, and schizophrenia.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lumosity DTx has joined the FNIH Biomarkers Consortium to conduct research toward the development of FDA-qualified digital biomarkers. This partnership supports the company's digital medicine initiatives and regulatory qualification efforts for quantitative behavioral measures used in predicting, diagnosing, or monitoring medical conditions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

100+ research partners across academic institutions and clinical settings participating in the Human Cognition Project. Researchers gain access to Lumosity tools, cognitive assessments, and de-identified datasets to conduct studies across disciplines including epidemiology, economics, clinical psychology, and educational psychology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborations with clinical research institutions studying populations including those with multiple sclerosis, Alzheimer's and other dementias, depression, cancer survivors, and other clinical conditions. Studies encompass both healthy and clinical populations of all ages.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prescription digital therapeutics company developing software-based treatments across neurology, psychiatry, and cardiometabolic indications. Closely comparable to Lumosity DTx in business model (prescription DTx) and clinical focus (neurological and mental health conditions).

2Pear Therapeutics
TypeDirect peer
Description

Pioneering prescription digital therapeutics company (reSET, reSET-O, Pear-008) that filed for bankruptcy in 2023. Historically the most prominent pure-play DTx peer to Lumosity DTx; remains a relevant benchmark for regulatory pathway, reimbursement risk, and the structural challenges of the category.

TypeDirect peer
Description

Consumer brain training app offering personalized cognitive exercises in memory, attention, and reasoning. Direct competitor to consumer Lumosity with similar product, target user, and subscription-based business model.

TypeDirect peer
Description

Provider of cognitive assessment and brain training software for consumers, clinicians, and researchers. Overlaps directly with both Lumosity Brain Training and the NCPT on assessment functionality and research-grade cognitive measurement.

TypeDirect peer
Description

Digital therapeutics company best known for EndeavorRx, an FDA-cleared prescription video game treatment for pediatric ADHD. Direct competitor to Lumosity DTx in the cognitive/neurological DTx space and the most analogous peer for the adult ADHD pivotal trial.

TypeDirect peer
Description

Developer of validated computerized cognitive assessments (e.g., CANTAB) used in clinical trials and by healthcare providers. Direct competitor to NCPT in the neuropsychological assessment market and a relevant peer for digital biomarker commercialization.

TypeDirect peer
Description

Mobile brain training app with daily cognitive exercises across math, reading, writing, and memory. Direct competitor in the consumer subscription brain-training category with overlapping audience and game-based training format.

TypeDirect peer
Description

Cognitive training platform with clinically validated brain exercises across memory, attention, and processing speed. Closest direct peer to consumer Lumosity and to the broader scientific brain-training category, with similar positioning around peer-reviewed efficacy.

TypeEmerging player
Description

Digital therapeutics company delivering FDA-cleared software for insomnia (Sleepio) and anxiety, with payer and employer distribution. Comparable DTx peer in clinical-grade cognitive/behavioral software and the same prescription/reimbursement go-to-market that Lumosity DTx is pursuing.

TypeEmerging player
Description

Digital mental health company combining consumer meditation content with clinician-led therapy and emerging clinical-grade mental health programs. Adjacent peer with overlap in consumer cognitive/wellness subscription and the broader digital mental health DTx category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

lumoslabs.com

Cognitive Training Softwarelumoslabs.com

Lumos Labs operates the Lumosity consumer brain training subscription and the NeuroCognitive Performance Test (NCPT), serving individual subscribers, 100+ academic and clinical research partners via the Human Cognition Project, and developing prescription digital therapeutics through its Lumosity DTx division.

What lumoslabs.com does

Lumos Labs, Inc. is a San Francisco-based private company founded in 2005 that operates a cognitive training and assessment platform under the Lumosity brand. Its core consumer product, Lumosity Brain Training, is a web- and mobile-based subscription program of 40+ game-based training tasks across cognitive domains including attention, memory, processing speed, problem solving, flexibility, and executive functioning. Daily sessions are 15 minutes across 5 games, with difficulty adapting to individual ability. Complementing this is the NeuroCognitive Performance Test (NCPT), a validated, web-based neuropsychological assessment of 17 subtests designed for at-home unsupervised use. The company runs the Human Cognition Project (HCP), a research collaboration program providing free access to its tools and de-identified datasets to 100+ qualified academic and clinical researchers; this program has produced 130+ peer-reviewed publications and currently supports 40+ ongoing studies.

The company's commercial model today is a consumer subscription for Lumosity, with research tools offered free to qualified investigators and ancillary professional services. In 2021, Lumos Labs launched Lumosity DTx, a digital therapeutics division developing prescription digital medicine for neurological and cognitive conditions. A pivotal clinical trial is underway in adult ADHD, with proof-of-concept programs across 19 clinical populations including mild cognitive impairment, stroke, Alzheimer's, cancer-related cognitive impairment, multiple sclerosis, and traumatic brain injury. The DTx division has joined the Foundation for the National Institutes of Health Biomarkers Consortium to pursue FDA-qualified digital biomarkers. The company is incorporated in the United States, headquartered in San Francisco, and serves a global footprint through web, iOS, and Android channels.

lumoslabs.com firmographics

Firmographics
Name
lumoslabs.com
Legal name
Lumos Labs, Inc.
Website
https://lumoslabs.com
Company type
Private
Founded year
2005
Operating status
Operating
Short description
Lumos Labs operates the Lumosity consumer brain training subscription and the NeuroCognitive Performance Test (NCPT), serving individual subscribers, 100+ academic and clinical research partners via the Human Cognition Project, and developing prescription digital therapeutics through its Lumosity DTx division.
Ownership category
akta.pro rank

lumoslabs.com industry classification

Industry
Product category
Cognitive Training Software
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs

Keywords

  • Cognitive training software
  • Digital therapeutics
  • Neuropsychological assessment
  • Brain training games
  • Cognitive assessment platform

Where lumoslabs.com is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

lumoslabs.com business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Lumosity Consumer Subscription: Lumosity brain training program offered to consumers through subscription model, available on web and mobile platforms. The platform serves individual users who pay for access to cognitive training games.
  2. Digital Therapeutics (DTx): Development of FDA-cleared digital medicine products for neurological and cognitive conditions. Pending clinical results, Lumosity DTx plans to seek FDA clearance for prescription DTx products targeting conditions such as adult ADHD.
  3. Research Data Access: Through the Human Cognition Project, researchers gain access to de-identified cognitive data subsets from Lumosity or NCPT. While tools are provided free to qualified researchers, this represents data monetization through research collaborations that advance scientific understanding and product development.
  4. Research Services: Lumos Labs scientists provide support on study design, data analysis, secure data storage, and regular delivery of study data for research collaborators.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree access for qualified researchers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

lumoslabs.com product offering

Product offering

Core offering

Lumos Labs develops and operates Lumosity, a web and mobile cognitive training platform offering more than 40 brain training games spanning memory, attention, and problem solving domains. The company also provides the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment, and offers de-identified cognitive datasets plus paid research collaboration services (study design, data analysis, secure storage, data delivery) through the Human Cognition Project (HCP). The Lumosity DTx division develops prescription digital therapeutics for neurological conditions, with a pivotal clinical trial underway for adult ADHD.

Product overview

Lumos Labs operates a platform-plus-services model centered on cognitive training and assessment. The core product is Lumosity Brain Training, a program of 40+ cognitive games that adapt to individual ability levels. Complementing this is the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment with 17 subtests. The Human Cognition Project (HCP) provides researchers access to Lumosity software and historical datasets for academic studies. In 2021, the company launched Lumosity DTx as a new division focused on developing FDA-regulated digital therapeutics, with a pivotal clinical trial underway for adult ADHD treatment and proof-of-concept programs for conditions including MCI, stroke, and Alzheimer's Disease.

Differentiator

Problem solved

Functional benefit

Brands

  • Lumosity: Brain training program including 40+ game-based training tasks spanning cognitive domains such as Attention, Memory, and Problem Solving.
  • Lumosity DTx
  • Human Cognition Project (HCP)
  • NeuroCognitive Performance Test (NCPT)

Products and services

  • Lumosity Brain Training A cognitive training program with more than 40 game-based training tasks spanning cognitive domains including Attention, Memory, Problem Solving, Cognitive Flexibility, Processing Speed, and Executive Functioning. Training consists of 15-minute daily sessions with 5 games each day, with difficulty adapting to individual abilities. Distributed via web and mobile apps to individual consumers.
  • NeuroCognitive Performance Test (NCPT) A validated, brief, repeatable, modular, online neuropsychological assessment platform designed by Lumos Labs for at-home, unsupervised use through a web browser. Includes 17 subtests based on well-known neuropsychological assessments measuring memory, processing speed, reasoning, attention, and cognitive flexibility. Can be administered in clinical settings.
  • Lumosity DTx Digital therapeutics division developing prescription DTx products for neurological and cognitive conditions. Currently conducting pivotal clinical trial for adult ADHD treatment, with proof-of-concept programs for MCI, stroke, Alzheimer's, cancer-related cognitive impairment, multiple sclerosis, TBI, ASD, PTSD, and schizophrenia.

Quantifiable outcome

  • 130+ peer-reviewed articles from research collaborations
  • +2 more outcomes

Companies that use lumoslabs.com

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

lumoslabs.com technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

lumoslabs.com partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Foundation for the National Institutes of Health (FNIH) Biomarkers ConsortiumcoreStrategic or Co-development PartnerLumosity DTx has joined the FNIH Biomarkers Consortium to conduct research toward the development of FDA-qualified digital biomarkers. This partnership supports the company's digital medicine initiatives and regulatory qualification efforts for quantitative behavioral measures used in predicting, diagnosing, or monitoring medical conditions.
  • Human Cognition Project Research CollaboratorscoreStrategic or Co-development Partner100+ research partners across academic institutions and clinical settings participating in the Human Cognition Project. Researchers gain access to Lumosity tools, cognitive assessments, and de-identified datasets to conduct studies across disciplines including epidemiology, economics, clinical psychology, and educational psychology.
  • Clinical Research InstitutionscoreStrategic or Co-development PartnerCollaborations with clinical research institutions studying populations including those with multiple sclerosis, Alzheimer's and other dementias, depression, cancer survivors, and other clinical conditions. Studies encompass both healthy and clinical populations of all ages.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

lumoslabs.com competitors and assessment

Company assessment

Direct peers

  • Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across neurology, psychiatry, and cardiometabolic indications. Closely comparable to Lumosity DTx in business model (prescription DTx) and clinical focus (neurological and mental health conditions).
  • Pear Therapeutics: Pioneering prescription digital therapeutics company (reSET, reSET-O, Pear-008) that filed for bankruptcy in 2023. Historically the most prominent pure-play DTx peer to Lumosity DTx; remains a relevant benchmark for regulatory pathway, reimbursement risk, and the structural challenges of the category.
  • NeuroNation: Consumer brain training app offering personalized cognitive exercises in memory, attention, and reasoning. Direct competitor to consumer Lumosity with similar product, target user, and subscription-based business model.
  • CogniFit: Provider of cognitive assessment and brain training software for consumers, clinicians, and researchers. Overlaps directly with both Lumosity Brain Training and the NCPT on assessment functionality and research-grade cognitive measurement.
  • Akili Interactive: Digital therapeutics company best known for EndeavorRx, an FDA-cleared prescription video game treatment for pediatric ADHD. Direct competitor to Lumosity DTx in the cognitive/neurological DTx space and the most analogous peer for the adult ADHD pivotal trial.
  • Cambridge Cognition: Developer of validated computerized cognitive assessments (e.g., CANTAB) used in clinical trials and by healthcare providers. Direct competitor to NCPT in the neuropsychological assessment market and a relevant peer for digital biomarker commercialization.
  • Elevate Labs: Mobile brain training app with daily cognitive exercises across math, reading, writing, and memory. Direct competitor in the consumer subscription brain-training category with overlapping audience and game-based training format.
  • Posit Science (BrainHQ): Cognitive training platform with clinically validated brain exercises across memory, attention, and processing speed. Closest direct peer to consumer Lumosity and to the broader scientific brain-training category, with similar positioning around peer-reviewed efficacy.

Emerging players

  • Big Health: Digital therapeutics company delivering FDA-cleared software for insomnia (Sleepio) and anxiety, with payer and employer distribution. Comparable DTx peer in clinical-grade cognitive/behavioral software and the same prescription/reimbursement go-to-market that Lumosity DTx is pursuing.
  • Headspace Health: Digital mental health company combining consumer meditation content with clinician-led therapy and emerging clinical-grade mental health programs. Adjacent peer with overlap in consumer cognitive/wellness subscription and the broader digital mental health DTx category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

lumoslabs.com financial estimates

Financial estimate

Revenue estimate

Valuation estimate

lumoslabs.com leadership team

Management profile

Number of profiles

lumoslabs.com funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

lumoslabs.com M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about lumoslabs.com

What does lumoslabs.com do?

Lumos Labs develops and operates Lumosity, a web and mobile cognitive training platform offering more than 40 brain training games spanning memory, attention, and problem solving domains. The company also provides the NeuroCognitive Performance Test (NCPT), a validated web-based neuropsychological assessment, and offers de-identified cognitive datasets plus paid research collaboration services (study design, data analysis, secure storage, data delivery) through the Human Cognition Project (HCP). The Lumosity DTx division develops prescription digital therapeutics for neurological conditions, with a pivotal clinical trial underway for adult ADHD.

Is lumoslabs.com a public or private company?

lumoslabs.com is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was lumoslabs.com founded?

lumoslabs.com was founded in 2005.

Where is lumoslabs.com based?

lumoslabs.com is headquartered in San Francisco, United States, in the North America region.

How does lumoslabs.com make money?

Four revenue lines are on record. Lumosity Consumer Subscription is the primary driver. The others are digital Therapeutics (DTx), research Data Access and research Services.

Who are lumoslabs.com's main competitors?

Direct peers on record are Click Therapeutics, Pear Therapeutics, NeuroNation, CogniFit, Akili Interactive, Cambridge Cognition, Elevate Labs and Posit Science (BrainHQ). Emerging players are Big Health and Headspace Health.

Does lumoslabs.com have an API?

No public API is recorded for lumoslabs.com.

What industry is lumoslabs.com in?

lumoslabs.com's product category is Cognitive Training Software. Its primary akta.pro industry code is HLAKAIAH, Cognitive & Behavioral Neurology (Dementia/Memory Disorders), with a secondary code of HLAGAAAG, Medical Writing & Regulatory Submission Support CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsLumos Labs Unveils Lumosity Research PlatformLumos Labs launched the Lumosity Research Platform, integrating cognitive assessments, digital training, participant recruitment, and real-world data for cognitive research. The platform supports studies from single assessments to large-scale randomized controlled trials, building on Lumosity's Human Cognition Project with over 1.5 million participants.B2B SaaS BlogLumos Labs (Lumosity) Revenue 2025: $6.8M Est. ARRLumos Labs is estimated to have reached an Annual Recurring Revenue (ARR) of $6.8 million in 2025 through its brain training platform, Lumosity. The company develops cognitive games based on neuropsychological research and maintains a collaborative initiative called the Human Cognition Project with over 90 universities.Business Wire BlogLumosity Announces FDA Clearance of LumosityRx, a Prescription Digital Therapeutic for Adults with ADHDLumos Labs received 510(k) clearance from the U.S. Food and Drug Administration for LumosityRx, a prescription digital therapeutic designed to improve attention in adults with ADHD. The approval is based on results from the GAMES Study, a clinical trial involving over 500 participants which demonstrated statistically significant improvements in attention compared to a control group. This clearance marks a strategic expansion for the company from consumer brain training apps into clinically validated medical treatments.GoogleLumosity: Brain Training GamesLumosity, developed by Lumos Labs, Inc., is a brain training app used by over 100 million people worldwide to enhance cognitive skills through various games. The app offers personalized training workouts and detailed insights, making it accessible to individuals of all ages interested in improving their mental agility. Recent updates include improvements to game functionality and tools for tracking progress.PR NewswireUnited States Education Apps Market 2016 - Key Vendors are Duo Lingo, Edmodo, Lumos Labs, Rosetta Stone & WizIQResearch and Markets announced the addition of its "Education Apps Market in the US 2015-2019" report to its offerings. The study projects a 31% CAGR for the US education apps market, driven by e-learning adoption and device penetration. Key competitors identified include Duolingo, Edmodo, Lumos Labs, Rosetta Stone, WizIQ, Google, Apple, and Microsoft.PR NewswireGame Based Learning Market to See 6% CAGR to 2019 With BreakAway, LearningWare, Lumos Labs and PlayGen.com Playing a Major RoleThe global game-based learning market is forecast to grow at a 6.47% CAGR from 2014 to 2019, with BreakAway, LearningWare, Lumos Labs, and PlayGen.com highlighted as key players. Demand for mobile educational games is rising due to smartphone adoption, while gamification is expected to boost corporate learning and reduce attrition.Business InsiderAnd Now The 25 Smartest Cities In AmericaLumos Labs ranked 25 U.S. cities by Lumosity test scores, with Charlottesville, Virginia, leading. College and university towns dominated the list, and large gaps in reported scores suggest the list could use further development.TechCrunchiPhone App Roundup: Week 3A weekly iPhone app roundup features six apps, including iInterface for remote computer control, TiniWiki for offline Wikipedia, and Lumos Labs brain-training games. Prices range from free to $7.99, with TiniWiki requiring a 7GB download. The roundup notes upcoming price cuts for some apps.TechCrunchLumos Labs Gets $3 Million Funding for Brain GamesLumos Labs raised $3 million from Pequot Ventures, Norwest Venture Partners, and angel investors. The company's brain fitness games have 330,000 unique visitors in April, with a potential 10% conversion rate. The funding aims to support growth as older adults seek to slow cognitive decline.TechCrunchAre you as smart as a chimp?A demo of Lumosity, a brain-training app from Lumos Labs, was shown, revealing the narrator's lethargy. The app includes scientific studies and a free trial, with a test against Ayumu, a 7-year-old chimp.